1. Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia
by Charles Koller, B. Nebiyou Bekele, Xian Zhou, Charles Park, Zeev Estrov, Susan O'Brien, Michael Keating, Iman Jilani, Francis J. Giles, Hagop M. Kantarjian, and Maher Albitar
Blood
Volume 108(3):
August 1, 2006
©2006 by American Society of Hematology

2. Association of Rai stage and plasma thrombopoietin levels.
Association of Rai stage and plasma thrombopoietin levels. Box plots showing levels of TPO in various Rai stages. Number (N) of patients in each stage is shown in parenthesis. Brackets indicate the value nearest to the 1.5× interquartile range. Outliers are shown as horizontal lines.
Charles Koller et al. Blood 2006;108:
©2006 by American Society of Hematology

3. Classification tree for all 127 patients.
Classification tree for all 127 patients. The number of patients who died in each group is shown first, and then the total number of patients. RR indicates relative risk.
Charles Koller et al. Blood 2006;108:
©2006 by American Society of Hematology

4. Kaplan-Meier estimates of patients' time to death grouped by plasma TPO levels.
Kaplan-Meier estimates of patients' time to death grouped by plasma TPO levels. Patients with TPO level higher than 639 pg/mL show significantly shorter survival.
Charles Koller et al. Blood 2006;108:
©2006 by American Society of Hematology

5. Co-plots of Kaplan-Meier estimates of survival in CLL
Co-plots of Kaplan-Meier estimates of survival in CLL. One-hundred and twenty-seven patients were separated into 4 groups based on their TPO and β2-microglobulin (B2M) levels.
Co-plots of Kaplan-Meier estimates of survival in CLL. One-hundred and twenty-seven patients were separated into 4 groups based on their TPO and β2-microglobulin (B2M) levels. The solid line represents the Kaplan-Meier estimates of overall survival for each group. The 95% confidence intervals of the survival curves are presented using the dotted lines. Each tick mark represents the time at which patients were censored.
Charles Koller et al. Blood 2006;108:
©2006 by American Society of Hematology

6. Kaplan-Meier survival estimates for previously untreated CLL patients.
Kaplan-Meier survival estimates for previously untreated CLL patients. Patients with TPO level higher than 308 pg/mL show significantly shorter survival.
Charles Koller et al. Blood 2006;108:
©2006 by American Society of Hematology